CLOPSY is used for the treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome [LGS], a difficult-to-treat form of childhood epilepsy.
CLOPSY binds at distinct binding sites associated with the chloride ionophore at the post-synaptic GABA receptor. These GABA receptors are in various locations in the CNS (limbic, reticular formation) and clobazam increases the duration of time for which the chloride ionopore is open. As a result, hyper polarization and stabilization of the membrane occur as the post-synaptic inhibitory effect of GABA is enhanced.
After oral administration of CLOPSY, it is almost completely absorbed (87% of dose). Tmax: 1-3 hours; Vdss: 100L; Protein-bound: 80-90% Elimination via the urine (̴ 94%) as metabolites. Half-life of CLOPSY 40mg is 32 hours.
A daily dose of CLOPSY greater than 5mg should be administered n divided doses twice daily; a 5mg daily dose can be administered as a single dose.
CLOPSY is available in 5 and 10mg tablet Each strip contains 10 tablets